Market Overview

UPDATE: Jefferies Raises PT to $23 on Solazyme Post Q3 Beat

Related SZYM
UPDATE: Morgan Stanley Downgrades Solazyme On Lack Of Conviction In Long-Term Outcome
Mid-Morning Market Update: Markets Edge Lower; Humana Profit Misses Estimates

Jefferies reiterated its Buy rating on Solazyme (NASDAQ: SZYM) and raised its price target from $22 to $23.

Jefferies commented, "Q3 was $0.06 better than consensus ($0.05 above our forecast). The current projects remain on track, but the real milestones were Bunge expanding its plans even before Moema starts, a new agreement with ADM, another tailored food oil and a test marketing program for Soladiesel. The focus now shifts to winning downstream partnerships."

Solazyme closed at $7.09 on Wednesday.

Latest Ratings for SZYM

DateFirmActionFromTo
Nov 2014Morgan StanleyDowngradesOverweightEqual-weight
Nov 2014Credit SuisseMaintainsNeutral
Nov 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for SZYM
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (SZYM)

Around the Web, We're Loving...

Get Benzinga's Newsletters